Illumina

Illumina today confirmed David P. King’s election to its Board of Directors. CEO Jacob Thaysen said: “David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders.” Read more: https://lnkd.in/gfyMe6hK

Today we’re celebrating another year of meaningful progress and impact with the release of our 2025 Corporate Responsibility Report.    Genomics has transformed how we understand disease, discover new therapies, and deliver more precise care—but too often, the benefits of these breakthroughs remain unevenly distributed. Illumina is focused on closing the access gap.     Our 2025 Corporate Responsibility Report, released today, outlines the ways in which we strive to increase equitable access to genomics, nurture our people and communities, integrate sustainability, and operate responsibly. Find our report here: https://lnkd.in/g6Z262Ta

It was a privilege to join President Trump as part of the U.S. business delegation to the U.S.-China Summit last week in Beijing. It was an important opportunity to represent Illumina and engage with officials and industry leaders on the future of innovation, health, and global collaboration. These conversations reinforced something I have long believed: expanding the impact of genomics requires sustained engagement, mutual understanding, and long-term commitment to progress. At Illumina, we see genomics as one of the most powerful forces shaping the future of medicine. Advancing global access means continuing to invest, partner, and serve customers around the world—so that more people everywhere can benefit from the discoveries, diagnostics, and improved health outcomes that genomics makes possible. Thank you to the U.S. government for the invitation and for organizing a meaningful visit. [Photo credit: U.S. Embassy 2026]

Illumina is redefining whole-genome sequencing, bringing the accuracy and ease of short-read sequencing to comprehensive, genome-wide insight.   Running on the NovaSeq X with no additional equipment required, TruPath™ expands access to whole-genome sequencing and reveals historically dark regions of the genome for innovators around the world.   Learn more 🔗 : https://lnkd.in/g5eUT56H

When the challenge is clinical adoption of genomics 🧬 — who you gonna call? Illumina Medical Affairs! Meet our US-Canada team supporting reproductive health and genetic disease testing. From publishing research that informs payer guidelines, to educating healthcare providers, to helping laboratories make the clinical and economic case for genomic testing, this crew plays a critical role. 🔗 Read our spotlight on this team and how they’re working behind the scenes to bring genomics into mainstream care: https://lnkd.in/gWQgauaB

Ovarian cancer is notoriously difficult to catch early — with a diagnostic journey that can be invasive and imprecise. Bodour Salhia, Ph.D, Professor of Cancer Biology at the Keck School of Medicine of the University of Southern California is using multiomics to advance early detection by improving the ability to distinguish between cancerous and non-cancerous tumors. In a research study she used Illumina Connected Multiomics to interrogate methylation, protein, and spatial data — improving tumor classification and revealing insights traditional methods may miss. ➡️ Read the full feature to learn how Illumina’s integrated technology is advancing research into new screening tools for ovarian cancer: https://lnkd.in/eh4-ZQZh

Bloomberg featured CEO Jacob Thaysen to discuss the company’s Q1 earnings report and confidence in continued growth ahead. “We see a lot of strength in the clinical space, and particularly in oncology.” As Illumina continues its strategy, we’re focused on supporting clinical stakeholders to get the right treatment at the right time to more cancer patients. Watch the full interview on Bloomberg: https://lnkd.in/gcP7HZbH

In the first quarter of 2026, we accelerated our strategy across AI insights, genomic and multiomic innovation, and clinical strength. Here are the highlights 👇    🔶 Unlocking speed and scale for drug discovery: We introduced the Billion Cell Atlas, the most comprehensive map of human disease biology to help train the next generation of AI models for drug target identification.    🔶 Driving the insight ecosystem: With the launch of TruPath™ Genome we delivered the simplest workflow for comprehensive whole-genome variant detection. We also unveiled a roadmap of NovaSeq™ X advancements including Q70 accuracy + 35B flow cells, and our customers shared new data that illustrates the impact of our multiomics portfolio.     🔶 Strengthening customer access to proteomic insights at scale: We officially welcomed the SomaLogic team to Illumina, helping customers generate rich multiomic datasets in support of better outcomes for patients.     🔶 Advancing our global clinical strategy: Dr. Eric Green joined Illumina as Chief Medical Officer to help advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data. Learn more at https://www.illumina.com/

What does it take to power the next wave of AI-driven drug discovery? Biological data—at an entirely new scale. The Billion Cell Atlas is designed to deliver just that: a first-of-its-kind resource built to train AI models for precision medicine and drug target identification. Hear directly from Kyle Kai-How Farh MD PhD , VP & Distinguished Scientist at Illumina, and explore the full story: https://lnkd.in/guhpN4nz

🎥 In celebration of #DNADay, Illumina employees around the world went back to the classroom to show students how genomics can help address global challenges. 🧬 Through hands‑on science and career conversations, employees connected thousands of learners with the people behind the science—helping make careers in genomics feel more personal and possible. What made this campaign especially meaningful was the collective participation: educators welcomed volunteers into their learning spaces, and students showed up with curiosity, enthusiasm, and excitement about what a future in STEM could look like. The future is bright indeed, and we can’t wait to see how the STEM leaders of tomorrow help expand access to genomic breakthroughs around the world. Happy DNA Day! Learn more at: dnaday.org